- CARDIOVASCULAR DISEASE
- METABOLIC SYNDROME
The risk of death tripled in patients with gout and visible tophi at diagnosis3*
All-cause mortality increased by 9% with every 1-mg/dL increase in sUA level4†
*Among patients with gout for less than 10 years with tophi at baseline (based on a 5-year observational study of 295 adults).3
†Based on a meta-analysis of 14 studies involving 341,389 adults.4
sUA, serum uric acid.
Patients with high sUA levels saw a ~2x greater risk of cardiovascular mortality5*
Gout has been shown to be an independent risk factor for heart failure, hypertension, CHD, PAD, PVD, and stroke2,6
*Cardiovascular mortality, RR 2.09 (95% CI, 1.45-3.02); all-cause mortality, RR 1.80 (95% CI, 1.39-2.34) after adjustment for potential confounders in a random-effects model.5
CHD, coronary heart disease; PAD, peripheral arterial disease; PVD, peripheral vascular disease; RR, relative risk.
Studies show gout is a risk factor for developing type 2 diabetes and is associated with metabolic syndrome2,7
As sUA levels increase, so does the prevalence of metabolic syndrome, and the sUA levels are positively associated with the development of type 2 diabetes.8
sUA, serum uric acid level.